Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Beigene Ltd (ADR)    BGNE

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

BeiGene : Presents Preliminary Phase 1 Data for BGB-A317 in Chinese Patients with Advanced Tumors at the 20th Annual Meeting of CSCO

share with twitter share with LinkedIn share with facebook
share via e-mail
09/29/2017 | 01:12pm CEST

BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today presented preliminary data from the dose-verification portion of the ongoing Phase 1/2 trial of its investigational anti-PD-1 antibody BGB-A317 in Chinese patients with advanced solid tumors at the 20th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in Xiamen, China. The preliminary data suggest that BGB-A317 was generally well tolerated and exhibited preliminary evidence of anti-tumor activity in a Chinese study population with advanced solid tumors. BeiGene and Celgene Corporation have a global strategic collaboration for BGB-A317 for solid tumors; BeiGene retains exclusive rights to BGB-A317 in China.

BGB-A317 was generally well tolerated and showed preliminary activity in a heavily pretreated study population with advanced solid tumors. At the time of the data cut-off, no dose-limiting toxicities were observed. The pharmacokinetic profile in Chinese patients was consistent with that reported in global trials of BGB-A317 at the registrational dose, commented Professor Lin Shen of the Peking University Cancer Hospital and Beijing Institute for Cancer Research, Beijing, China, the lead author of the abstract.

This dose-verification trial is an important step as we advance BGB-A317 along Chinas domestic innovative drug development pathway. Two registrational trials of BGB-A317, in urothelial cancer and classical Hodgkin lymphoma, are currently ongoing in China. The Celgene partnership allows us to increase our investment in BGB-A317, and we intend to initiate Phase 3 trials supporting approval in China for each of the four most common tumors in the country including lung, stomach, liver, and esophageal cancers, with the initial studies expected to start in the fourth quarter of 2017 or first quarter of 2018, commented Amy Peterson, MD, Chief Medical Officer, Immuno-oncology at BeiGene.

Summary of Results from the Ongoing Phase 1/2 Trial

The multi-center Phase 1/2 trial of BGB-A317 consists of a Phase 1 dose-verification portion and a Phase 2 portion of indication expansion in disease-specific cohorts. Data presented at CSCO include patients enrolled in the Phase 1 portion of this study, who received BGB-A317 at 200 mg once every three weeks (Q3W).

As of June 16, 2017, 20 patients had enrolled in the trial. The median duration of therapy in these patients was 53 days (range 21171 days).

Adverse events (AEs) assessed by the investigator to be related to treatment occurred in 19 patients (95%). The most common treatment-related AEs (TRAEs) were related to changes in clinical laboratory value; TRAEs occurring in 15% or more of patients included increased blood bilirubin (45%), anemia (35%), proteinuria (30%), increased aspartate transferase (AST) (25%), increased alanine transferase (ALT) (20%), leukopenia (15%), neutropenia (15%), pyrexia (15%), and vomiting (15%). All of the TRAE cases were grades 1 or 2 except for one case each of grade 3 increased blood bilirubin, leukopenia, and neutropenia. Increased AST (25%) and ALT (20%) were the most common AEs that were potentially immune related.

At the time of the data cutoff, 11 patients had at least one post-baseline imaging assessment, and three patients had at least two imaging assessments. The efficacy-evaluable population (measurable disease at baseline and at least one post-baseline tumor assessment, or progression or death) consisted of 12 patients, including three patients with microsatellite-instability-high (MSI-high) colorectal cancer (CRC), two patients with gastric cancer (GC), two patients with hepatocellular carcinoma (HCC), two patients with urothelial cancer (UC), two patients with melanoma, and one patient with gastrointestinal stromal tumor (GIST). Partial responses (PR) were observed in one patient with UC (confirmed) and one with GC (unconfirmed). Stable disease was observed in two patients with melanoma and one with MSI-high CRC. In the remaining eight patients who were not evaluable as of the data cutoff, a third unconfirmed PR was observed in a patient with esophageal cancer 11 days after the data cutoff. At the time of the data cutoff, 15 patients remained on treatment.

About BGB-A317

BGB-A317 is an investigational humanized monoclonal antibody that belongs to a class of immuno-oncology agents known as immune checkpoint inhibitors. It is designed to bind to PD-1, a cell surface receptor that plays an important role in downregulating the immune system by preventing the activation of T-cells. BGB-A317 has high affinity and specificity for PD-1. It is differentiated from the currently approved PD-1 antibodies in an engineered Fc region, which is believed to minimize potentially negative interactions with other immune cells. BGB-A317 is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. BeiGene and Celgene Corporation have a global strategic collaboration for BGB-A317 for solid tumors.

(c) 2017 TehranTimes. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

Stocks mentioned in the article
ChangeLast1st jan.
BEIGENE LTD (ADR) 0.57% 165.05 Delayed Quote.68.90%
CELGENE CORPORATION -0.08% 85.78 Delayed Quote.-17.80%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BEIGENE LTD (ADR)
07/09BEIGENE : Announces Inducement Grants Under NASDAQ Listing Rule 5635(4)
07/03BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
06/20BEIGENE : Provides Development Update and Presents Clinical Data on Zanubrutinib..
06/15BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
06/15BeiGene Provides Development Update and Presents Clinical Data on Zanubrutini..
06/08BEIGENE, LTD. : Change in Directors or Principal Officers, Submission of Matters..
06/06BeiGene to Present at the Goldman Sachs 39th Annual Global Healthcare Confere..
06/05BEIGENE : to Present at the William Blair 2018 Growth Stock Conference
06/01BeiGene to Present Data on Zanubrutinib and Host an Investor Call from the 23..
05/21BEIGENE LTD (ADR) : Blog Exposure - BeiGene Commenced Phase-3 Trial of Pamiparib..
More news
News from SeekingAlpha
06/303 THINGS IN BIOTECH, JUNE 30 : Aptose Gets Rolling Again; Tesaro Heads To China;.. 
06/21MIRATI THERAPEUTICS : How Much Higher Can This 'Rocket' Go? 
06/193 THINGS IN BIOTECH, JUNE 18 : Some More Good Heme News! 
06/18BeiGene (BGNE) EHA Update On BTK Inhibitor Zanubrutinib And The Clinical Deve.. 
06/18YOUR DAILY PHARMA SCOOP : Selecta Bio Reports Positive, Acceleron And Atara Move.. 
Financials ($)
Sales 2018 114 M
EBIT 2018 -371 M
Net income 2018 -436 M
Finance 2018 925 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 69,0x
EV / Sales 2019 65,4x
Capitalization 8 823 M
Duration : Period :
Beigene Ltd (ADR) Technical Analysis Chart | BGNE | US07725L1026 | 4-Traders
Technical analysis trends BEIGENE LTD (ADR)
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 199 $
Spread / Average Target 21%
EPS Revisions
John V. Oyler Chairman & Chief Executive Officer
Xiao Bin Wu President
Maggie Liu Head-Operations
Howard Liang Chief Financial & Strategy Officer
Amy C. Peterson Chief Medical Officer-Immuno-Oncology
Sector and Competitors
1st jan.Capitalization (M$)
BEIGENE LTD (ADR)68.90%8 823
GENMAB8.36%10 693